This clinical trial evaluates whether a Tai Chi training program is feasible for improving balance and nerve function in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a complication of chemotherapy drugs that can cause damage to the nerves in the hands and feet. CIPN can involve pain and/or other problems, including tingling, numbness, and motor weakness. These symptoms may lead to difficulty maintaining balance while performing everyday physical activities (such as walking or running), and they may increase the risk of falls and interfere with quality of life. Tai Chi is a mind-body practice that has emerged as an accessible approach for balance training to enhance lower extremity strength in older adults. It has been shown to be effective in improving gait health, posture control, and pain relief. Tai Chi may have positive effects on balance and nerve function in cancer survivors with CIPN.
Additional locations may be listed on ClinicalTrials.gov for NCT06807294.
Locations matching your search criteria
United States
Massachusetts
Boston
Brigham and Women's HospitalStatus: Active
Contact: Peter Wayne
Dana-Farber Cancer InstituteStatus: Active
Contact: Ting Bao
Phone: 857-215-2844
PRIMARY OBJECTIVES:
I. Evaluate the feasibility and acceptability of a 12-week Tai Chi program among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).
II. Assess changes in gait and balance from baseline to 12 weeks in each intervention arm.
III. Evaluate changes in pain severity and nerve function from baseline to 12 weeks in each intervention arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients participate in virtual Tai Chi training sessions twice weekly, over 60 minutes each, for 12 weeks. Patients are also instructed to practice Tai Chi at home three days a week for 60 minutes per day.
ARM II: Patients receive standard CIPN care per their primary care physician or oncologist for 12 weeks. After the 12 weeks, patients are offered the virtual Tai Chi training sessions as in Arm I.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorTing Bao
